dc.contributor | Faculdade de Medicina do ABC (FMABC) | |
dc.contributor | Universidade Federal de São Paulo (UNIFESP) | |
dc.contributor | Universidade Estadual Paulista (Unesp) | |
dc.date.accessioned | 2014-05-27T11:28:10Z | |
dc.date.available | 2014-05-27T11:28:10Z | |
dc.date.created | 2014-05-27T11:28:10Z | |
dc.date.issued | 2013-01-16 | |
dc.identifier | International Archives of Medicine, v. 6, n. 1, 2013. | |
dc.identifier | 1755-7682 | |
dc.identifier | http://hdl.handle.net/11449/74387 | |
dc.identifier | 10.1186/1755-7682-6-2 | |
dc.identifier | 2-s2.0-84872131878 | |
dc.identifier | 2-s2.0-84872131878.pdf | |
dc.description.abstract | Background: Several studies seek biological markers that give diagnostic and degree of tumor development. The aim of this study was to validate the determination of plasma DNA using nanotechnology (Nanovue™-NV) in samples of 80 patients with prostate cancer. Methods. Blood samples of 80 patients of the Urology Ambulatory of Faculdade de Medicina do ABC with prostate cancer confirmed by anatomical-pathology criteria were analyzed. DNA extraction was performed using a GFX TM kit (Amersham Pharmacia Biotech, Inc, USA) following the adapted protocol. Plasma was subjected to centrifugation. Results: There was a big difference between the first and the second value obtained by NanoVue Only two samples had no differences between duplicates. Maximum difference between duplicates was 38 μg/mL. Average variation between 51 samples was 10.29 μg/mL, although 21 samples had differences above this average. No correlation was observed between pDNA obtained by traditional spectrophotometry and by nanotechnology. Conclusion: Determination of plasma DNA by nanotechnology was not reproducible. © 2013 Moreno et al; licensee BioMed Central Ltd. | |
dc.language | eng | |
dc.relation | International Archives of Medicine | |
dc.relation | 0,237 | |
dc.rights | Acesso aberto | |
dc.source | Scopus | |
dc.subject | DNA | |
dc.subject | Nanotechnology | |
dc.subject | Neoplams | |
dc.subject | Prostate | |
dc.subject | blood level | |
dc.subject | blood sampling | |
dc.subject | cancer patient | |
dc.subject | centrifugation | |
dc.subject | DNA determination | |
dc.subject | DNA extraction | |
dc.subject | human | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | nanotechnology | |
dc.subject | prostate cancer | |
dc.subject | reliability | |
dc.subject | spectrophotometry | |
dc.title | Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer | |
dc.type | Artículos de revistas | |